(19)
(11)EP 3 670 534 A3

(12)EUROPEAN PATENT APPLICATION

(88)Date of publication A3:
09.09.2020 Bulletin 2020/37

(43)Date of publication A2:
24.06.2020 Bulletin 2020/26

(21)Application number: 19200863.9

(22)Date of filing:  13.04.2011
(27)Previously filed application:
 13.04.2011 PCT/US2011/032333
(51)Int. Cl.: 
C07K 16/28  (2006.01)
A61K 39/395  (2006.01)
A61P 3/00  (2006.01)
A61P 3/06  (2006.01)
A61P 43/00  (2006.01)
A61P 3/10  (2006.01)
A61P 1/16  (2006.01)
A61P 3/04  (2006.01)
A61P 9/00  (2006.01)
C07K 16/40  (2006.01)
(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 15.04.2010 US 32469110 P
13.10.2010 US 39285910 P

(62)Application number of the earlier application in accordance with Art. 76 EPC:
11715374.2 / 2558497

(71)Applicant: Amgen Inc.
Thousand Oaks, California 91320-1799 (US)

(72)Inventors:
  • Fachini, Roger
    Thousand Oaks, CA 91360-5344 (US)
  • Foltz, Ian
    Burnaby, British Columbia V5A 4B9 (CA)
  • Han, Seog Joon
    Simi Valley, CA 93063 (US)
  • Harris, Susie Miki
    Newbury Park, CA 91320 (US)
  • Hu, Shaw-Fen Sylvia
    Thousand Oaks, CA 91360 (US)
  • King, Chadwick Terence
    North Vancouver, British Columbia V7L 3T5 (CA)
  • Li, Yang
    Mountain View, CA 94040 (US)
  • Lu, Ji
    Thousand Oaks, CA 91320 (US)
  • Michaels, Mark Leo
    Encino, CA 91316 (US)
  • Sun, Jeonghoon
    Thousand Oaks, CA 91320 (US)

(74)Representative: Altmann Stößel Dick Patentanwälte PartG mbB 
Dudenstrasse 46
68167 Mannheim
68167 Mannheim (DE)

  


(54)HUMAN FGF RECEPTOR AND BETA-KLOTHO BINDING PROTEINS


(57) The present invention provides compositions and methods relating to or derived from antigen binding proteins and antigen binding protein-FGF21 fusions that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins and antigen binding protein-FGF21 fusions induce FGF21-like signaling. In some embodiments, an antigen binding protein or antigen binding protein-FGF21 fusion antigen binding component is a fully human, humanized, or chimeric antibody, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to β-Klotho, or β-Klotho and one or more of FGFR1c, FGFR2c, FGFR3c, and FGFR4. Other embodiments provide nucleic acids encoding such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, cells comprising such polynucleotides, methods of making such antigen binding proteins and antigen binding protein-FGF21 fusions, and fragments and derivatives thereof, and polypeptides, and methods of using such antigen binding proteins and antigen binding protein-FGF21 fusions, fragments and derivatives thereof, and polypeptides, including methods of treating or diagnosing subjects suffering from type 2 diabetes, obesity, NASH, metabolic syndrome and related disorders or conditions.